CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were granted on December 22, 2022, and vest as to one-quarter of the shares on December 31, 2023 and as to an additional one-quarter of the shares at the end of each successive year thereafter, subject to the employee's continued service with Syros. These awards are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros' 2022 Inducement Stock Incentive Plan.

About Syros Pharmaceuticals

More on Boston Chron

• Boston: March 2023: Latest Updates from the Mayor's Office of Housing
• Boston: April Allston/Brighton Community Center Study Meeting
• Boston: Mayor Wu Launches $750,000 Grant Fund to Support Growth of Businesses and Access to City Contracts
• Mayor Wu Announces $4 Million Investment to Expand Boston's Tuition Free Community College Program
• Boston: Meet the Fine Arts Work Center Scholarship Recipients

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

More on Boston Chron

• Boston: The Mary Eliza Project: Ward 3 Voter Records Now Available
• Boston AIR Spotlight: Ellice Patterson and Boston Transportation Department
• Mayor Wu Announces Applications Open for the 2023-2024 SPARK Boston Council
• Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
• Mayor Wu Announces Events in Remembrance of the 2013 Boston Marathon

Contacts

Syros
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com

Media
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-813-767-7801
bleigh@lifescicomms.com

Investors
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

---

Show All News | Report Violation